Search Results - "Fontanals, S"

Comments on “Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines” by Ibáñez, C., Fontanals, S., Mesia, R., Clopés, A.

Get full text

A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial by Moreno-González, G, Mussetti, A, Albasanz-Puig, A, Salvador, I, Sureda, A, Gudiol, C, Salazar, R, Marin, M, Garcia, M, Navarro, V, de la Haba Vaca, I, Coma, E, Sanz-Linares, G, Dura, X, Fontanals, S, Serrano, G, Cruz, C, Mañez, R

“…Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the…”
Get full text

P-251 Denudation time is crucial to increase the proportion of top-quality embryos in egg donation cycles by Martiñá Rivas, L, Rovira Fontanals, S, Rovira Ripoll, M, Acín Vinyeta, L, De Rocco, M, Moffa, F, Antich Díaz, M, Novo Bruña, S

“…Abstract Study question How do different denudation times affect in the efficiency of the egg donation cycles? Summary answer Undetected in vitro matured…”
Get full text

P-242 ICSI, the sooner, the better by Peinado Adiego, L, Rovira Fontanals, S, Lolicato, F, Rodriguez Isern, A, Pérez-Alzueta, A, Moffa, F, Antich Díaz, M, Novo Bruña, S

“…Abstract Study question What is the impact of different ICSI timing on the efficiency of egg reception cycles concerning both denudation and trigger events?…”
Get full text

P-250 Only euploidy does not ensure optimal chances for successful live birth through single blastocyst cryotransfer by Rovira Fontanals, S, Tribbioli, G, Company Regàs, D, Ruiz Porras, P, Moreno Tierz, A, Moffa, F, Antich Díaz, M, Novo Bruña, S

“…Abstract Study question What does a euploid blastocyst require to provide the greatest probability of successful birth? Summary answer Morphokinetic and…”
Get full text

1758P Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA) by Hierro, C., Notario Rincon, L., Esteve Gomez, A.M., González, A., Llenas, A., Horneros, J., Ibáñez, C., Fontanals, S., Clopes, A., Mesia Nin, R., Arribas, L.

Get full text

Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient by Fort, E, Otero, S, Moliner, P, Bleda, C, Prats, J, Nadal, E, Palmero, R, Jimenez, L, Piulats, J M, Rey, M, Fontanals, S

“…Abstract Background Oral anticancer therapy is increasingly integrated into the care of patients (pts) with cancer. Recognition and management of…”
Get full text

1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore) by Notario Rincon, L., Hierro, C., Esteve, A., Fontanals, S., González, A., Loureiro, E., Sun, C., Margelí, M., Moran, T., Font, A., Manzano, J.L., Balaña, C., Quiroga, V., Quer, N., Ibañez, C., Martínez-Benavides, J., Brunet, J., Clopes, A., Mesia, R.

Get full text

Unveiling body composition as prognostic factor in metastatic cancer patients (PT) treated with molecularly-targeted agents (MTA) or immunotherapy (IO) by Arribas, L., Llenas, A., González-Valencia, A., Notario, L., Horneros, J., Fontanals, S., Mesía, R., Esteve, A., Hierro, C.

Get full text

72P Prevalence and potential consequences of drug-drug interactions in oncohematological patients treated with oral antineoplasic drugs by Fort, E., Otero, S., Simon, S. Pernas, Nadal, E., Sanchez, R. Palmero, Piulats, J.M., Senin, A., Oliveira, A.C., Bleda, C., Prats, J., Rey, M., Fontanals, S.

Get full text

67P Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program by Rincon, L. Notario, Arribas, L., Esteve, A., González, A., Llenas, A., Horneros, J., Ibáñez, C., Fontanals, S., Clopes, A., Nin, R. Mesia, Hierro, C.

Get full text

240P Effect of dose intensity (DI) of palbociclib (PAB) and initial body weight dosage (BWD) on progression free survival (PFS): A real-world data analysis in patients with hormone-receptor (HR) positive HER2 negative metastatic breast cancer (MBC) by Penabad, S. Recalde, Fort, E., Otero, S., Lezcano, C., Gil, V.L. Obadia, Sabaté, N., Juher, H. Pla, Falgas, E. Felip, Vila, M. Margeli, Villaro, G. Vinas, Gomez, A.M. Esteve, Rey, M., Simon, S. Pernas, Fontanals, S.

Get full text

Low dose of cyclophosphamide related to myocardiopathy by Fontanals, S, Cañete, C, Soy, D, Castro, P, Nicolás, J M

Get full text

Miocardiopatía por ciclofosfamida a dosis bajas by Fontanals, S., Cañete, C., Soy, D., Castro, P., Nicolás, J.M.

Get full text

Description of the ISO 9001/2000 certification process in the parenteral nutrition area by Miana Mena, M T, Fontanals Martínez, S, López Púa, Y, López Suñé, E, Codina Jané, C, Ribas Sala, J

“…In order to guarantee quality and safety and to increase user satisfaction, healthcare organisations have integrated quality management systems into their…”
Get full text

Descripción del proceso de certificación ISO 9001/2000 en el área de nutrición parenteral by Miana Mena, M.T., Fontanals Martínez, S., López Púa, Y., López Suñé, E., Codina Jané, C., Ribas Sala, J.

“…Garantizar la calidad y seguridad e incrementar la satisfacción del usuario ha llevado a organizaciones del ámbito sanitario a integrar un sistema de gestión…”
Get full text